Fifth Third Bancorp Boosts Stake in Edwards Lifesciences Corporation $EW

Fifth Third Bancorp grew its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 499.2% during the first quarter, HoldingsChannel reports. The firm owned 142,677 shares of the medical research company’s stock after acquiring an additional 118,867 shares during the period. Fifth Third Bancorp’s holdings in Edwards Lifesciences were worth $11,426,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in EW. WealthShield Partners LLC lifted its position in Edwards Lifesciences by 2.1% during the first quarter. WealthShield Partners LLC now owns 27,185 shares of the medical research company’s stock worth $2,177,000 after buying an additional 553 shares in the last quarter. Candriam S.C.A. increased its stake in shares of Edwards Lifesciences by 10.8% in the 1st quarter. Candriam S.C.A. now owns 260,327 shares of the medical research company’s stock worth $20,847,000 after acquiring an additional 25,359 shares during the last quarter. Sequoia Financial Advisors LLC increased its stake in shares of Edwards Lifesciences by 5.8% in the 1st quarter. Sequoia Financial Advisors LLC now owns 35,328 shares of the medical research company’s stock worth $2,829,000 after acquiring an additional 1,948 shares during the last quarter. Equitable Trust Co. increased its stake in shares of Edwards Lifesciences by 7.6% in the 1st quarter. Equitable Trust Co. now owns 69,444 shares of the medical research company’s stock worth $5,561,000 after acquiring an additional 4,896 shares during the last quarter. Finally, Waterfront Wealth Inc. raised its holdings in shares of Edwards Lifesciences by 5.7% during the 1st quarter. Waterfront Wealth Inc. now owns 16,341 shares of the medical research company’s stock worth $1,309,000 after acquiring an additional 887 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $83.01, for a total transaction of $84,587.19. Following the transaction, the vice president owned 33,934 shares of the company’s stock, valued at approximately $2,816,861.34. This trade represents a 2.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the transaction, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. This represents a 3.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 45,577 shares of company stock valued at $3,855,527 in the last ninety days. Insiders own 0.31% of the company’s stock.

Edwards Lifesciences Price Performance

EW stock opened at $90.06 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The firm has a market capitalization of $51.86 billion, a P/E ratio of 47.91, a P/E/G ratio of 2.30 and a beta of 0.86. The business’s 50-day moving average is $87.04 and its two-hundred day moving average is $83.92. Edwards Lifesciences Corporation has a 1 year low of $72.30 and a 1 year high of $96.29.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The firm’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on EW. BTIG Research boosted their target price on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Royal Bank Of Canada increased their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday. Wolfe Research upgraded shares of Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 price target for the company in a report on Wednesday, April 1st. Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Finally, Citigroup upped their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $98.27.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.